Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/20/2026 | $17.00 | Overweight → Equal Weight | Barclays | |
| 4/16/2026 | $2.65 | Neutral → Sell | UBS | |
| 4/8/2026 | $6.00 | Buy → Hold | HSBC Securities | |
| 4/3/2026 | $19.00 | Neutral → Buy | BofA Securities | |
| 4/2/2026 | $19.00 | Neutral → Buy | BofA Securities | |
| 4/1/2026 | $4.59 | Market Perform → Outperform | Itau BBA | |
| 4/1/2026 | $92.00 | Peer Perform → Outperform | Wolfe Research | |
| 3/13/2026 | $5.60 | Underperform → Hold | Jefferies |
6-K - ULTRAPAR HOLDINGS INC (0001094972) (Filer)
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Merlin, Inc. (NASDAQ:MRLN), an aerospace and defense technology company building the operating system of record for autonomous flight, today announced the composition of its Board of Directors following the closing of Merlin Labs, Inc.'s business combination with Inflection Point Acquisition Corp. IV and the commencement of trading on the Nasdaq Global Market on March 17, 2026. The Board is composed of seven directors, including founder and CEO Matt George as Chairman, and six directors determined to be independent under Nasdaq listing rules. "Each of our directors brings a distinct and complementary perspective, from serving as Secretary of the
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and heal
SÃO PAULO, April 10, 2026 /PRNewswire/ -- Azul Brazilian Airlines ((B3:AZUL53, OTC:AZLUY) announces that it filed its Form 20-F annual report for fiscal year 2025 with the U.S. Securities and Exchange Commission (SEC) on April 2nd, 2026. The report is available on the SEC's website at www.sec.gov and on Azul's Investor Relations website at ri.voeazul.com.br. Azul's shareholders and holders of American depositary shares can also request the document from Azul's Investor Relations department.About Azul Azul S.A. ((B3: AZUL53, OTC:AZULQ), the largest airline in Brazil in terms of cities served, offers more than 800 daily flights to 137 destinations. With an operational fleet of around 200 airc
Barclays downgraded Vale S.A. from Overweight to Equal Weight and set a new price target of $17.00
UBS downgraded AmBev from Neutral to Sell and set a new price target of $2.65
HSBC Securities downgraded Ultrapar Participacoes from Buy to Hold and set a new price target of $6.00
4 - Itau Unibanco Holding S.A. (0001132597) (Issuer)
4 - Itau Unibanco Holding S.A. (0001132597) (Issuer)
4 - Banco Santander (Brasil) S.A. (0001471055) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
SINGAPORE, Dec. 17, 2025 /PRNewswire/ -- UATP, the global network enabling organizations to simplify payment processes and expand their payment capabilities, announced today the appointment of David Newington as Managing Director, Commercial, Asia-Pacific, effective immediately. With more than 25 years of leadership experience spanning Payments, IT, and Corporate Travel, Newington brings a proven track record of driving growth, building high-performing teams, and delivering customer-centric solutions across Australia, the United States, and Singapore. In this role, Newington w
Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp
SÃO PAULO, Oct. 13, 2025 /PRNewswire/ -- GOL Linhas Aéreas Inteligentes S.A. (B3: GOLL54) ("GOL" or "Company"), one of the main airlines in Brazil, in compliance with article 157, paragraph 4, of Law No. 6,404/76 and the Resolution of the Brazilian Securities and Exchange Commission No. 44/2021 ("Resolution CVM 44"), hereby informs its shareholders and the market in general that, on this date, the Company's Board of Directors approved, among other matters, the convening of General Meetings to deliberate on the proposed merger of the Company and Gol Investment Brasil S.A., a privately held corporation registered with the CNPJ/MF under No. 55.012.370/0001-30 ("GIB"), into Gol Linhas Aéreas S.A
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and heal
SÃO PAULO, Feb. 23, 2026 /PRNewswire/ -- 4Q25 Highlights Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of R$2.4 billion in 4Q25, 13% lower than in 3Q25 and in line with 4Q24. Notably, North America accounted for 62% of the Company's Consolidated EBITDA in 2025.Investments (CAPEX) of R$1.5 billion in 4Q25, totaling R$6.1 billion in 2025. For 2026, the approved investment plan projects R$ 4.7 billion in CAPEX.Dividend distribution of R$0.10 per share, equivalent to R$197.5 million, to be paid based on March 18, 2026. In 2025, Gerdau S.A. distributed R$2.4 billion to shareholders through dividend and share buybacks, reaching a 182.3% shareholder return.The Com
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $
SC 13G - AZUL SA (0001432364) (Subject)
SC 13G - GERDAU S.A. (0001073404) (Subject)
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)